Archives

  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2018-07

    • Prochlorperazine-Induced Hemidystonia as a Stroke Mimic: Cli

    2026-07-07

    Prochlorperazine-Induced Hemidystonia: A Stroke Mimic Unveiled

    Study Background and Research Question

    Acute ischemic stroke remains a critical medical emergency, with rapid administration of fibrinolytics significantly improving outcomes. However, the urgency to treat can sometimes overshadow the systematic exclusion of stroke mimics—non-vascular conditions that present with similar neurological deficits. The reference study (Mimicking Acute Stroke) investigates a unique clinical scenario where a commonly used dopamine D2 receptor antagonist, prochlorperazine, triggered hemidystonia, which was initially mistaken for a cerebrovascular event in a pregnant patient. The central research question: How can clinicians reliably distinguish drug-induced neurological syndromes from true acute stroke, especially under time-sensitive conditions?

    Key Innovation from the Reference Study

    The innovation of this case report lies in its detailed characterization of prochlorperazine-induced hemidystonia as a clinical stroke mimic. To the authors' knowledge, this is the first published instance where prochlorperazine, widely employed as an antiemetic agent for nausea and vomiting, directly precipitated unilateral dystonic symptoms indistinguishable from acute stroke at presentation. This finding urges clinicians and researchers to broaden their differential diagnosis and medication review protocols when faced with atypical neurological deficits, especially in populations at increased risk for both drug side effects and cerebrovascular disease.

    Methods and Experimental Design Insights

    The study uses a single-patient clinical case format, typical for rare adverse event documentation but methodologically robust in its systematic assessment and exclusion of alternative diagnoses. On presentation, the 32-year-old pregnant patient exhibited sudden-onset slurred speech, left-sided pain, and profound hemiparesis. Standard stroke activation protocols were initiated, including comprehensive neurological examination, urgent head CT imaging, and a battery of laboratory tests (chemistry, liver function, coagulation, and blood count), all of which were unremarkable. A critical methodological insight is the team's rapid reassessment when additional extrapyramidal signs became evident—specifically, repetitive involuntary tongue movements. This led to a focused medication review, revealing recent initiation of prochlorperazine at standard antiemetic doses (4 x 10 mg oral doses within 24 hours). The definitive diagnostic maneuver was the administration of intravenous diphenhydramine, which resolved the motor symptoms within minutes, confirming a diagnosis of acute dystonia rather than vascular stroke. Subsequent MRI ruled out ischemic pathology, and close inpatient observation ensured full recovery.

    Protocol Parameters

    • Patient weight and dosing context: 67 kg; received 4 x 10 mg oral prochlorperazine within 24 hours, last dose 1 hour before symptom onset—aligning with typical antiemetic therapy regimens.
    • Acute dystonia management: 50 mg intravenous diphenhydramine administered at onset of extrapyramidal symptoms, with rapid resolution of motor deficits.
    • Diagnostic workflow: Immediate code stroke activation, neuroimaging, and extensive laboratory workup to exclude ischemic and metabolic causes.
    • Observation period: Overnight inpatient monitoring for recurrent dystonia and neurological sequelae.
    Workflow recommendations for in vitro or translational studies should account for prochlorperazine's known extrapyramidal risk at clinically relevant doses (see product information), and consider pre-screening for confounding neurological phenotypes in experimental models.

    Core Findings and Why They Matter

    The central finding—prochlorperazine-induced hemidystonia presenting as a stroke mimic—carries significant implications for both clinical and translational neuroscience. The case demonstrates that antiemetic therapy with dopamine D2 receptor antagonists can precipitate severe, focal extrapyramidal symptoms, especially in susceptible populations such as pregnant women. The rapid resolution with antihistaminergic treatment (diphenhydramine) not only clarifies the diagnosis but also prevents unnecessary exposure to fibrinolytic therapies, which carry substantial risks. For researchers, this case highlights the importance of meticulous medication history-taking in both clinical practice and experimental modeling. It also underscores the necessity of distinguishing true neurological injury from pharmacologically-induced syndromes, particularly when evaluating new agents or repurposing existing drugs in cancer research or neuropharmacology.

    Comparison with Existing Internal Articles

    The reference case report provides a clinically grounded perspective on prochlorperazine's neurological risk profile, complementing the mechanistic and translational focus of several existing internal resources. For example, the article "Prochlorperazine: Mechanistic Leverage in Translational Oncology" explores the compound's multi-receptor pharmacology and its expanding role in melanoma research and infection biology. These sources describe prochlorperazine as a versatile dopamine D2 receptor antagonist with additional effects on histamine, muscarinic, and adrenergic receptors, underpinning its use in both antiemetic therapy and as an inhibitor of melanoma cell proliferation and migration. Furthermore, another internal article discusses the agent's antiviral and anticancer properties, including its ability to block clathrin-mediated endocytosis and regulate MITF and tyrosinase in melanoma cells. While these studies focus on in vitro and translational applications, the clinical case report cautions that the same pharmacological properties that confer therapeutic benefit can also yield serious adverse effects such as dystonia, which may be mistaken for cerebrovascular events if not carefully distinguished.

    Limitations and Transferability

    As a single case report, the study's generalizability is inherently limited. The rarity of prochlorperazine-induced hemidystonia (especially as a stroke mimic) restricts its immediate applicability to broader patient populations. However, the diagnostic and therapeutic workflow presented is highly transferable as a model for evaluating acute neurological syndromes with ambiguous etiology, both in clinical and research settings. The findings serve as a cautionary exemplar for translational oncology and neuropharmacology research, where dopamine D2 receptor antagonists are increasingly repurposed for antitumor or antiviral studies. Rigorous preclinical screening for extrapyramidal side effects is warranted when deploying prochlorperazine in experimental systems—especially at concentrations paralleling those used in clinical antiemetic therapy (typically 1–10 μM in vitro, as noted in product documentation).

    Why this cross-domain matters, maturity, and limitations

    The clinical evidence of prochlorperazine's potential to induce acute dystonia bridges emergency neurology and translational research domains. While the reference study emphasizes acute diagnostic strategies in the emergency department, internal literature documents prochlorperazine's growing application in melanoma research and tamoxifen-resistant breast cancer research. This cross-domain relevance underscores the dual necessity of leveraging the drug's mechanistic breadth while maintaining vigilance for its neurological liabilities. However, extrapolation from single-patient clinical data to in vitro or animal models must be done cautiously, as interspecies and system-specific pharmacodynamics may differ.

    Research Support Resources

    For researchers modeling prochlorperazine's diverse pharmacological effects—whether in antiemetic therapy, melanoma research, or antiviral studies—a rigorously characterized reagent is essential. Prochlorperazine (SKU A8508) from APExBIO offers a standardized, research-grade compound suitable for in vitro and translational workflows, with recommended concentrations ranging from 1–10 μM. While the clinical case report underscores potential neurological side effects, careful titration and context-appropriate controls can help mitigate these risks in experimental protocols.